C. Arriens

发表

Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus

E. Chakravarty, J. Guthridge, J. Merrill, 2021, Journal of translational autoimmunity.

Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study

E. Chakravarty, J. Guthridge, J. Merrill, 2020, EClinicalMedicine.

Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy

A. Reimold, L. Feagins, C. Arriens, 2015, European journal of gastroenterology & hepatology.

A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus

K. Kalunian, C. Putterman, J. Conklin, 2021, ACR open rheumatology.

Ancestry-based differences in the immune system are associated with lupus severity

P. Khatri, H. Maecker, J. Guthridge, 2021 .

Cell-bound complement activation products associate with lupus severity in SLE

Ghalib A. Bello, K. Kalunian, C. Putterman, 2020, Lupus Science & Medicine.

Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers

E. Chakravarty, J. Merrill, S. Kamp, 2020, Lupus Science & Medicine.

Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial

N. Olsen, D. Liao, D. Karp, 2019, Arthritis care & research.

Systemic lupus erythematosus biomarkers: the challenging quest

J. Wren, C. Mohan, M. Munroe, 2016, Rheumatology.

Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death.

D. Karp, E. Chakravarty, J. Merrill, 2017, Clinical immunology.

Resistin as a potential marker of renal disease in lupus nephritis

Tianfu Wu, J. Hutcheson, Tianfu Wu, 2015, Clinical and experimental immunology.

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures

E. Chakravarty, J. Merrill, J. James, 2019, Lupus Science & Medicine.

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

B. Rovin, S. Navarra, Y. Teng, 2021, The Lancet.

Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.

L. Davis, J. Hutcheson, Tianfu Wu, 2016, Clinical immunology.

Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints

B. Rovin, K. Kalunian, J. Sánchez-Guerrero, 2020, Kidney International Reports.

OP0277 AURORA PHASE 3 STUDY DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN)

I. Adzerikho, N. Solomons, C. Arriens, 2020 .

Systemic lupus erythematosus diagnostics in the 'omics' era.

C. Mohan, C. Arriens, Cristina Arriens, 2013, International journal of clinical rheumatology.

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

K. Kalunian, C. Putterman, D. Wallace, 2019, Arthritis & Rheumatology (Hoboken, N.j.).

Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.

H. Maecker, E. Chakravarty, J. Guthridge, 2020, The Journal of allergy and clinical immunology.

Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study.

M. Petri, Tianfu Wu, C. Mohan, 2016, Journal of proteome research.

Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies

J. Guthridge, J. Merrill, J. James, 2021, Frontiers in Immunology.

Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis

T. Atsumi, A. Saxena, N. Solomons, 2022, Arthritis care & research.

Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial

N. Olsen, D. Liao, D. Karp, 2018, Trials.

Placebo-controlled randomized clinical trial of fish oil’s impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus

C. Mohan, D. Karp, L. Hynan, 2015, Nutrition Journal.

Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes

E. Lewis, B. Rovin, V. Jha, 2019, Arthritis & rheumatology.

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

K. Kalunian, C. Putterman, D. Wallace, 2019, Arthritis & rheumatology.

A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus

E. Chakravarty, J. Guthridge, D. Blankenship, 2022, Arthritis & rheumatology.

The SLE review series : working for a better standard of Care

J. Wren, C. Mohan, M. Munroe, 2016 .

Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial

S. Navarra, T. Atsumi, B. Satirapoj, 2023, Arthritis & rheumatology.

Ancestry-based differences in the immune phenotype are associated with lupus activity

P. Khatri, H. Maecker, J. Guthridge, 2023, JCI insight.

Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.

L. Davis, J. Hutcheson, Tianfu Wu, 2016, Clinical immunology.

D. Karp, E. Chakravarty, J. Merrill, 2017, Clinical immunology.

potential roles in

H. Maecker, J. Guthridge, J. Merrill, 2023 .